

Fournier's gangrene and diabetes mellitus: Our experience with 50 patients

Shivprasad Hirugade^{1*}, Harish N Patil², Shilpa S Hirugade³

¹Associate Professor, ²Assistant Professor, Department of General Surgery, RCSM Government Medical College, Kolhapur, Maharashtra.

³Consultant Pediatrician, Apple Hospital and Research Center, Kolhapur, Maharashtra.

Email: hirugade@gmail.com

Abstract

Introduction: Fournier's gangrene is a rare, rapidly progressive, necrotizing fasciitis of the external genitalia and perineum. In this study we aimed to share our experience as association of diabetes mellitus as most important and independent risk factor for development of Fournier's gangrene and its direct relation to mortality. **Methods:** This is a retrospective study of the patient admitted in RCSMGMC CPR Hospital from January 2015 to June 2016, of 50 patients with Fournier's gangrene and diabetes mellitus to analyze association of diabetes mellitus for development of Fournier's gangrene and as a prognostic indicator of mortality. **Results:** All the 50 patients were male. The mean age was 48 years (range 30– 75 years). Average length of treatment was 25.8 days (from 14 to 36 days). The most common predisposing factor was diabetes mellitus (100%). E. coli was the most frequent bacterial organisms cultured. Etiology of FG was perianal infection in 36 patients (72 %), Urogenital infection in 11 patients (22 %), and skin infection in 3 patients (6 %). All patients were treated with a common approach of resuscitation, broad-spectrum antibiotics, and wide surgical excision. The mortality rate was 24%. The advanced age, renal failure on admission, extension of infection to the abdominal wall, occurrence of septic shock and need for postoperative mechanical ventilation are the main prognostic factors of mortality. Dm was not determined as a risk factor for mortality. **Conclusions:** Fournier's gangrene is still a very severe disease with high mortality rates. Early recognition of infection associated with invasive and aggressive treatment is essential to reduce these prognostic indices. Our hypothesis is that the key of the successful treatment is to treat as soon as symptoms onset, early and aggressive necrosectomy under broad antibiotic coverage. Dm was not determined as a risk factor for mortality.

Keywords: Fournier's gangrene, Mortality, diabetes mellitus, Outcome analysis.

*Address for Correspondence:

Dr. Shivprasad Hirugade, Associate Professor, Department of General Surgery, RCSM Government Medical College, Kolhapur, Maharashtra, INDIA.

Email: hirugade@gmail.com

Received Date: 05/07/2016 Revised Date: 13/08/2016 Accepted Date: 03/09/2016

Access this article online

Quick Response Code:	Website: www.statperson.com
	DOI: 12 September 2016

INTRODUCTION

Fournier's gangrene (FG) is a rare, rapidly progressive, fulminant form of necrotizing fasciitis of the genital, perianal and perineal regions, which may extend up to the abdominal wall between the fascial planes¹. The scrotum readily develops dermal gangrene because it has virtually

no subcutaneous fat between the epidermis and dartos muscle. These infections are typically polymicrobial, with both aerobic and anaerobic organisms present in the majority of cases.^{2,3,4} The cause of infection is identifiable in 95% of cases, mainly arising from anorectal, genitourinary and cutaneous sources.⁵ Predisposing factors such as diabetes and Immunosuppression lead to vascular disease and suppressed immunity that increase susceptibility to polymicrobial Infection. Common predisposing conditions include lower socioeconomic status, state of uncleanliness and poor personal hygiene, generalised debilitating diseases, alcoholism, steroid use, cancer chemotherapy or presence of diabetes⁶. Diagnosis is based on clinical signs and physical examination. Radiological methods may help to delineate the extent of the disease. Its treatment is unique for all cases including emergency removal of the devitalized tissues, adequate resuscitation, and intravenous (iv) administration of wide-

spectrum antibiotics.^{3,7} Fournier's Gangrene Severity Index (FGSI) has become a standard index and being routinely used as a good predicting tool^{8,9}. Acute Physiology and Chronic Health Evaluation (APACHE) II scoring system is a commonly used method for predicting outcomes of critically ill patients with necrotizing soft tissue infection (NSTI).¹⁰ The mortality rate for FG is still very high, at 20–50% in most of the studies^{11,12}. Fortunately, it is a rare condition, with a reported incidence of 1.6/100,000 males with peak incidence in the 5th and 6th decades. However, the incidence is rising, most likely due to increased numbers of patients on immunosuppressive therapy or suffering from human immunodeficiency virus (HIV) infection^{13,14}. Fournier's gangrene may occur in both sexes but is less reported in females.^{11,15} A similar infection can occur in women with necrotising infection of the vulva or perineum, and sometimes may be secondary to Bartholin's cyst or abscess¹⁶. Vulvar phacomycosis occurs in diabetics and mimics necrotising fasciitis¹⁷. Worldwide DM is the most common medical comorbidity condition in Fournier's gangrene.¹⁸ Early diagnosis, aggressive resuscitation of the patient, administration of broad-spectrum antibiotics and aggressive radical surgical debridement(s), are the key of successful treatment. In this study, we aimed to investigate patients with Fournier's Gangrene and association of diabetes mellitus as risk factors that affect mortality.

MATERIALS AND METHODS

This is a retrospective study of the patient admitted in RCMGMC CPR Hospital from January 2015 to June 2016, of 50 patients with Fournier's gangrene and diabetes mellitus. The inclusion criteria included diabetic patients undergoing wide surgical excision of scrotal and/or perineal skin with a diagnosis of Fournier's gangrene. All patients underwent at least one radical debridement of affected devitalized tissues within 12 hours after admission. IV third-generation cephalosporin antibiotic therapy was started at the emergency room and continued. Empiric antibiotic therapy was changed according to culture and sensitivity report. Wound dressings were changed daily. Repeated debridements were performed until healthy granulation tissue was formed in the wound. Skin defects were closed with staged tertiary closure with testicular repositioning in the thighs. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS II). The correlation of prognostic variables and mortality were studied by univariate analysis using chi-squared test and Fisher's exact probability test. P values less than 0.05 were considered as statistically significant.

RESULTS

Of the 50 patients studied, 12 died and 38 survived; the overall mortality rate was 24%. Most common cause of death was the multi-organ failure due to septic shock. All patients were male with a mean age of 48 years (range 30–75 years). The survivors (mean age 44 years) were significantly younger than the non-survivors (mean age 57 years) ($p < 0.001$). The source of infection was identified in all patients. The commonest source of sepsis was the anorectum (Table 1).

Table 1: Etiology in 50 patients with Fournier's gangrene

Etiology	Patients	%
Anal Abscess	31	62
Urogenital diseases	11	22
Thrombosed hemorrhoids	5	10
Skin infection	3	6
Total	50	100

Diabetes mellitus (DM) was the most common comorbidity associated with Fournier's gangrene and was present in all patients at the time of admission. The most common symptoms at the time of admission were deterioration of the general state (44%), perineal necrosis (92%), fever (60%), perineal or genital pain (76%), septic shock (22%). The average time of symptoms prior to referral to treatment was 11 days, ranging from 4 to 25 days. Mortality rate was higher among patients with symptom duration longer than 10 days. Regarding the investigations performed on admission, complete blood count showed the presence of a hyperleukocytosis ($> 10,000/\text{mm}^3$) in 39 patients (78%). 9 patients required blood transfusion. The mortality of the patients presented with renal failure (blood urea $> 50 \text{ mg / dl}$) on admission was significantly higher than the patient without renal failure. Fournier's gangrene was confined to the perineal area in 5 patients (10%), scrotum in 35 (70%) individuals and extending to the abdominal wall in 10 patients (20%). It was found that the extension of the infection to the abdominal wall was a predictor of mortality ($p < 0.003$) (55% in the non-survivors compared to 7% in the survivors). The most frequent bacterial organisms cultured from the wound sites were *Escherichia coli* (85.6%) and *Klebsiella* (40.5%). *Enterococci*, *Streptococci*, *Staphylococci*, *Pseudomonas* and *Proteus* were other microorganisms isolated in wound cultures, consecutively. Anaerobic culture could not be performed in our hospital because of technical difficulties. Before surgery, all patients underwent aggressive fluid resuscitation and were treated with third-generation cephalosporin and received hemodynamic support when required. Mechanical ventilation, continuous monitoring, and inotropic support were applied when necessary in patients with

cardiopulmonary failure due to sepsis. Majority of the debridement's were performed under spinal anesthesia; however, seven patients (14 %) required general anesthesia. All patients underwent radical surgical debridement, ranging from 1 to 10 procedures, with an average of 2.5. Debridement consisted of excision of all necrotic tissue, cleansing with hydrogen peroxide, then saline and drainage. Orchidectomy was carried out unilaterally for gangrenous testes in one patient (2%). Wounds of all patients were suitable for staged tertiary closure with testicular repositioning in the thigh. Fecal diversion with a temporary colostomy was not required in any patient. Of 50 patients, 11 patient required mechanical ventilation. Patients had a median hospital stay of 21 (range, 4–66) days. The significant predictors of mortality were the advanced age, presence of diabetes, and extension of the infection to the abdominal wall, renal failure and need of Mechanical ventilation (Table 2).

Table 2: Comparison of the patients' characteristics between survivors and non-survivors

Patient characteristics	Survivors n= 38	Non-survivors n = 12	p
Age (years, mean ± SD)	44	57	<0.001
Extension of the infection to the abdominal wall	7%	55%	<0.003
Renal failure	18	82	<0.001
Need of Mechanical ventilation	0%	91.6%	<0.0001

DISCUSSION

Fournier's gangrene, caused by synergistic aerobic and anaerobic organisms, is a life-threatening disorder in which infection of the perineum and scrotum spreads along fascial planes, leading to soft-tissue necrosis. In spite of the developing medical technology and experience, FG is still a fatal disease. There are several methods of mortality prediction including APACHE II score and FGSi which are commonly used traditional scoring systems. This infectious was initially described by Baurienne in 1764¹⁹. Before in 1883 Jean Alfred Fournier, French dermatologist described a syndrome of unexplained sudden onset and rapidly progressing gangrene in the penis and scrotum of 5 young men with no other pathology basis of sudden onset and rapid progression²⁰. In its early reports Fournier's gangrene was described as an idiopathic entity, but in most cases a perianal infection, urinary tract and local trauma or skin condition at that level can be identified¹³. The mortality rate for FG is still high, (20–50%) in most of the studies^{11,12}, despite an increased knowledge of the etiology, diagnosis and treatment, and intensive-care techniques. The high mortality reflects both the

aggressive nature of the infection and the destructive effects of accompanying predisposing factors. Several factors affecting the mortality were studied such as increasing age, primary anorectal infections, existence of diabetes, delay in treatment, evidence of systemic sepsis at presentation, extent and depth of involvement, a low haematocrit, a high leukocytosis and blood urea, a low serum albumin, and many others^{9,11-14,21}. FGSi is a scoring system first described by Laor *et al.* in 1995.²² It is a physiological and metabolic status based scoring system. It has been validated in several reported studies^{9,12}. Early diagnosis was reported to be associated with better outcomes in FG.²³⁻²⁶ Early surgical treatment within two days after admission reduces mortality of FG.²⁵ Also, the interval time between the onset of symptoms and initial debridement has been reported to be a major predictor of mortality.²⁶ The average age of the patients was 47.5 years, in most published series from 40.9 to 61.7 years^{11,13}. In a population based study of 1641 patients, Sorensen *et al.* found that an increasing patient age was the strongest independent predictor of mortality ($p < 0.0001$)¹³. Numerous factors have been implicated at the onset of FG, in particular, those involving the immune system²¹. Diabetes mellitus was the most reported co-morbid disease associated with this pathology. Some authors estimate the prevalence of DM among FG patients between 50 and 70 percent²⁷. There are other several studies showing DM as a risk factor for patients with FG.^{3,7,11,23} Nevertheless, there are also some studies where DM has been reported as one of the most frequent comorbidities but not determined as a risk factor for mortality ($p=0.429$).^{13,24} It is also suggested that renal failure on admission might be a noticeable factor for the prediction of the mortality rate²³. Among many laboratory parameters studied in FG, Clayton *et al.*, reported that only a level of blood urea $> 50\text{mg/dl}$ on admission was statistically significant for mortality²⁹. In our study we also found that renal failure on admission is significantly higher in non survivors. Few articles have highlighted the poor prognosis of FG in patients with a delay between time of presentation and treatment. This factor has been reported in a study by Jeong *et al.*, as a predictor of mortality³⁰. The most common origin of the FG was anorectal diseases (72%) in our study, followed by urogenital diseases (22%) and skin infections (6%). There are two previous studies reporting perianal abscess as the most common etiological factor.^{24,28} Extent to abdominal wall has been reported to be directly related to mortality³¹, which was confirmed in our series. Ultimately, occurrence of septic shock and need for postoperative mechanical ventilation, have been demonstrated as a powerful (even late) factors of mortality⁹. Furthermore, Yanar *et al.* found that the

presence of sepsis was as the only significant independent risk factor for mortality in FG³. Role of cystostomy and colostomy, are controversial as a treatment protocol and it should be applied in accordance to individual patient condition^{32,33}. Since mortality is the major problem for this devastating disease, extra attention is required for the management of the patients in high-risk group.

CONCLUSIONS

Fournier's gangrene is still a very severe disease with a high mortality rate. The advanced age, renal failure on admission, extension of infection to the abdominal wall, occurrence of septic shock and need for postoperative mechanical ventilation are the main prognostic factors of mortality. Early recognition of infection associated with invasive and aggressive treatment is essential for attempting to reduce these prognostic indices. Diabetes mellitus was the most reported co-morbid disease associated with this pathology. Although it was the most common co-morbidity among all patients, DM was not determined as a risk factor for mortality.

REFERENCE

1. Corman JM, Moody JA, Aranson WL: Fournier's gangrene in a modern surgical setting: improved survival with aggressive management. *Br J Urol Int* 1999, 84:85–88.
2. Morpurgo E, Galandiuk S: Fournier's gangrene. *Surg Clin North Am* 2002, 82:1213–1224.
3. Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, Baspinar I: Fournier's gangrene: risk factors and strategies for management. *World J Surg* 2006, 30:1750–1754.
4. Bjurlin MA, O'Grady T, Kim DY, Divakaruni N, Drago A, Blumetti J, et al. Causative pathogens, antibiotic sensitivity, resistance patterns, and severity in a contemporary series of Fournier's gangrene. *Urology* 2013; 81:752-8.
5. Paty R, Smith AD: Gangrene and Fournier's gangrene. *Urol Clin North Am* 1992, 19:149–162.
6. Lamerton AJ. Fournier's gangrene: Nonclostridial gas gangrene of perineum and diabetes mellitus. *Jr Soc Med* 1986; 79(4):212-7.
7. Martinschek A, Evers B, Lampl L, Gerngroß H, Schmidt R, Sparwasser C. Prognostic aspects, survival rate, and predisposing risk factors in patients with Fournier's gangrene and necrotizing soft tissue infections: evaluation of clinical outcome of 55 patients. *Urol Int* 2012; 89:173-9.
8. Roghmann F, von Bodman C, Löppenber B, Hinkel A, Palisaar J, Noldus J: Is there a need for the Fournier's gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier's gangrene. *BJU Int* 2012, 110:1359–1365.
9. Verma S, Sayana A, Kata S, Rai S: Evaluation of the utility of the Fournier's gangrene severity index in the Management of Fournier's gangrene in North India: A

- multicentre retrospective Study. *J Cutan Aesthet Surg* 2012, 5:273–276.
10. Yilmazlar T, Ozturk E, Alsoy A, Ozguc H. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. *World J Surg* 2007; 31:1858-62.
11. Eke N: Fournier's gangrene: a review of 1726 cases. *Br J Surg* 2000, 87:718–728.
12. Morua AG, Lopez JA, Garcia JD, Montelongo RM, Guerra LS: Fournier's gangrene: our experience In 5 Years, bibliographic review and assessment of the Fournier's gangrene severity index. *Arch Esp Urol* 2009, 62:532–540.
13. Sorensen MD, Krieger JN, Rivara FP, Klein MB, Wessells H: Fournier's gangrene: management and mortality predictors in a population based study. *J Urol* 2009, 182:2742–2747.
14. Ugwumba FO, Nnabugwu II, Ozoemena OF: Fournier's Gangrene – Analysis of management and outcome in South-Eastern Nigeria. *S Afr J Surg* 2012, 50:16–19.
15. Kouadio K, Kouame YJ, Bi KL, Turquin HH. Perineal gangrene: report of 30 cases. Observed at Abidjan. *Med Trop* 1998; 58: 245-248.
16. Kumar P, Mishra SM. Is idiopathic gangrene of scrotum (Fournier's gangrene) really idiopathic? *Ind J Surg* 1999; 61:243- 5.
17. Addison WA, Livengood Ch III et al. Necrotizing fasciitis of vulvar origin in diabetic patients. *Obstet Gynecol* 1984; 63; 473- 82.
18. Dahm P, Roland FH, Vaslef SN, Moon RE, Price DT, Georgiade GS. Outcome analysis in patients with primary Necrotizing fasciitis of the male genitalia. *Urology* 2000; 56: 31-35.
19. Smith GL, Bunker GB, Dinneen MD: Fournier's gangrene. *BJU* 1998, 81:347–355.
20. Fournier JA: Gangrene foudroyante de la verge. *Medecin Practique* 1883, 4:589–597.
21. Malik AM, Sheikh S, Pathan R, Khan A, Sheikh U: The spectrum of presentation and management of Fournier's gangrene-An Experience of 73 Cases. *J Pak Med Assoc* 2010, 60:617–619.
22. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. *J Urol* 1995; 154:89-92.
23. Aridogan IA, Izol V, Abat D, Karsli O, Bayazit Y, Satar N. Epidemiological characteristics of Fournier's gangrene: a report of 71 patients. *Urol Int* 2012; 89:457-61.
24. Kabay S, Yucel M, Yaylak F, Algin MC, Hacıoglu A, Kabay B, et al. The clinical features of Fournier's gangrene and the predictivity of the Fournier's Gangrene Severity Index on the outcomes. *Int Urol Nephrol* 2008; 40:997-1004.
25. Sugihara T, Yasunaga H, Horiguchi H, Fujimura T, Ohe K, Matsuda S, et al. Impact of surgical intervention timing on the case fatality rate for Fournier's gangrene: an analysis of 379 cases. *BJU Int* 2012; 110(11 Pt C):E1096-100.
26. Korkut M, İçöz G, Dayangaç M, Akgün E, Yeniay L, Erdoğan O, et al. Outcome analysis in patients with Fournier's gangrene: report of 45 cases. *Dis Colon Rectum* 2003; 46:649-52.

27. García A, Martín J, Vaquero A, Sánchez T, de Tomás J, Lago J, Turégano F: Fournier's gangrene: analysis of prognostic variables in 34 patients. *European Journal of Trauma and Emergency Surgery* 2011, 37:141–145.
28. Ersoz F, Sari S, Arikan S, Altıok M, Bektas H, Adas G, et al. Factors affecting mortality in Fournier's gangrene: experience with fifty-two patients. *Singapore Med J* 2012; 53:537-40.
29. Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK: Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. *Surg Gynecol Obstet* 1990, 170:49–55.
30. Jeong HJ, Park SC, Seo IY, Rim JS: Prognostic factors in Fournier gangrene. *Int J Urol* 2005, 12:1041–1044.
31. Ruiz-Tovar J, Córdoba L, Devesa JM: Prognostic Factors in Fournier Gangrene. *Asian J Surg* 2012, 35:37–41.
32. Kearney GP, Carling PC. Fournier's gangrene: an approach to its management. *J Urol* 1983; 130:695-8.
33. Woodside JR. Necrotizing fasciitis after neonatal circumcision. *Am J Dis Child* 1980; 134:301-2.

Source of Support: None Declared
Conflict of Interest: None Declared